Evenamide (NW-3509): Evidence of Anti-Psychotic Efficacy as an Add-On to Antipsychotics in Ongoing Phase 2 Study May Suggest an Alternative Approach to the Treatment of Schizophrenia

MILAN–(BUSINESS WIRE)–Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, announced today that it will present at the 5th Biennial Schizophrenia International Research Society Conference the abstract “Evenamide (NW-3509), a Putative Antipsychotic, Targets Abnormal Electrical Activity and Glutamatergic Abnormalities in Improving Psychotic Symptoms in Patients with Schizophrenia in a Phase II, Placebo-controlled Trial.”


Will be keeping an eye on this drug.

1 Like